Glenmark’s Digital Asthma Inhaler: Is It Really A Roaring Success?
Executive Summary
Just months into its launch, over 100,000 patients in India are said to be using Glenmark’s “Digihaler” for asthma and chronic obstructive pulmonary disorder (COPD) medication. But some key opinion leaders appear unconvinced of the disruptive potential of the firm’s next generation digital dose inhaler.
You may also be interested in...
Lupin-Aptar Launch India’s First Smart Device For MDIs At $22 Apiece
As the Indian pharma industry catches up with digitization, Lupin partners with Aptar to launch a smart device for MDIs. While there is a need for the product, whether it will find favor in a price-sensitive market remains to be seen.
Glenmark Wins ‘Milestone’ US Nod For COPD Trial In Innovation Push
India’s Glenmark sees the US FDA clearance of its Phase II plan for a novel formulation for COPD as a milestone in its quest to transform into a more innovation-led company and position itself for future growth.
Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?
Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.